- Home
- ROIV vs MASI Comparison
ROIV vs MASI Comparison
Compare ROIV & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | MASI |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 7.6B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ROIV | MASI |
|---|---|---|
| Price | $21.41 | $137.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $24.31 | ★ $188.80 |
| AVG Volume (30 Days) | ★ 8.3M | 748.8K |
| Earning Date | 02-09-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $20,329,000.00 | ★ $2,182,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $741.42 | $6.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.48 |
| 52 Week Low | $8.73 | $125.94 |
| 52 Week High | $23.47 | $194.88 |
Technical Indicators
Market Signals| Indicator | ROIV | MASI |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 51.67 |
| Support Level | $20.78 | $125.94 |
| Resistance Level | $22.21 | $131.95 |
| Average True Range (ATR) | 0.64 | 3.39 |
| MACD | -0.17 | 0.61 |
| Stochastic Oscillator | 27.11 | 93.96 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MASI Masimo Corporation
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.